AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7601015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for complicated urinary tract infections
Number of subjects: 0
Study 7601015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for lower respiratory tract infections
Number of subjects: 0
Study 7601015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for skin and soft tissue infections
Number of subjects: 0
Study 7601015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for pyelonephritis
Number of subjects: 0
Study 7601015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for bacterial enteritis
Number of subjects: 0
Study 7601015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for typhoid fever
Number of subjects: 0
Study 7601015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for bone and joint infections (preliminary studies)
Number of subjects: 0
Study 7601015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg/day orally or 400 mg/day orally or intravenously
Number of subjects: 0
Study 7601015 — intervention group
Group type: COMPARATOR
Intervention: Fleroxacin 400 mg once daily compared to ofloxacin 800 mg/day
Number of subjects: 0
Study 7601015 — intervention group
Group type: COMPARATOR
Intervention: Fleroxacin 400 mg once daily compared to ciprofloxacin 1000 mg/day
Number of subjects: 0
Study 7601015 — intervention group
Group type: COMPARATOR
Intervention: Fleroxacin 200 mg once daily compared to norfloxacin 800 mg/day
Number of subjects: 0
Study 2253290 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1.5% (0.35 ml.kg‐1) + norepinephrine (5 micrograms.ml‐1)
Number of subjects: 22
Study 2253290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% + norepinephrine
Number of subjects: 22
Study 2253290 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25%
Number of subjects: 22
Study 7343850 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical technique group I (64 cases): craniectomy with open dura mater fixed to lateral musculature
Number of subjects: 126
Study 7343850 — intervention group
Group type: COMPARATOR
Intervention: Surgical technique group II (62 cases): endotracheal intubation without head flexion, plastic closure of the dura
Number of subjects: 126
Study 31968063 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (Prehab) group
Number of subjects: 110
Study 31968063 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation (Rehab) group
Number of subjects: 110
Study 29361297 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest then Exercise
Number of subjects: 18
Study 29361297 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 18
Study 29361297 — intervention group
Group type: COMPARATOR
Intervention: Not having surgery
Number of subjects: 18
Study 27595693 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Degludec (IDeg)
Number of subjects: 7637
Study 27595693 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine U100 (IGlar)
Number of subjects: 7637
Study 27595693 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome (IDeg and IGlar)
Number of subjects: 7637
Study 25044079 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture at 37°C
Number of subjects: 52
Study 25044079 — intervention group
Group type: COMPARATOR
Intervention: Culture at 36°C
Number of subjects: 52
Study 22948779 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated carbon nanoparticle-epirubicin suspension
Number of subjects: 120
Study 22948779 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin control group
Number of subjects: 120
Study 22948779 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 20859315 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ibuprofen (4% gel, 320 mg total, 4 times daily for 2 weeks)
Number of subjects: 20
Study 20859315 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (2400 mg total, 3 times daily for 2 weeks)
Number of subjects: 20
Study 18420964 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (22 g/d loading for 5 days; maintenance 3.76 g/d during PR)
Number of subjects: 100
Study 18420964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18420964 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 100
Study 15871870 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant-heat dressing device
Number of subjects: 41
Study 15871870 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing (with or without calcium alginate filler)
Number of subjects: 41
Study 12651678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5% with epinephrine 1:200,000 (3 mL)
Number of subjects: 153
Study 12651678 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline (3 mL)
Number of subjects: 153
Study 11200792 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lysine acetylsalicylate (1620 mg) combined with metoclopramide (10 mg)
Number of subjects: 0
Study 11200792 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan (100 mg)
Number of subjects: 0
Study 11200792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8804681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (20 micrograms/kg per dosing)
Number of subjects: 18
Study 8804681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine combined with alcohol (0.5 g/kg)
Number of subjects: 18
Study 8804681 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone (0.5 g/kg)
Number of subjects: 18
Study 8804681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8804681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine alone
Number of subjects: 18
Study 8804681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine and alcohol combined
Number of subjects: 18
Study 1545087 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized allergen extracts (100,000, 10,000, and 1000 AU/ml)
Number of subjects: 0
Study 1545087 — intervention group
Group type: COMPARATOR
Intervention: Conventional nonstandardized extracts (1:10 or 1:20 wt/vol)
Number of subjects: 0
Study 1545087 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized and conventional extracts
Number of subjects: 0
Study 6432415 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin 3 mg b.d.
Number of subjects: 40
Study 6432415 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine 200 mg b.d.
Number of subjects: 40
Study 30871608 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (hemoglobin threshold of 9 g/dL)
Number of subjects: 44
Study 30871608 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (hemoglobin threshold of 7 g/dL)
Number of subjects: 44
Study 30135171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (navigators)
Number of subjects: 1877
Study 30135171 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 1877
Study 26762365 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital exercise training programme (aerobic interval training for 6 to 9 weeks)
Number of subjects: 46
Study 26762365 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (usual care and no formal exercise training)
Number of subjects: 46
Study 26762365 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital exercise training programme
Number of subjects: 46
Study 26762365 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 46
Study 24794760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and fentanyl (D/F)
Number of subjects: 60
Study 24794760 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and fentanyl (M/F)
Number of subjects: 60
Study 22245607 — intervention group
Group type: EXPERIMENTAL
Intervention: LBVH0101
Number of subjects: 185
Study 22245607 — intervention group
Group type: COMPARATOR
Intervention: Hiberix™
Number of subjects: 185
Study 20558806 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week group intervention plus transdermal nicotine replacement
Number of subjects: 360
Study 20558806 — intervention group
Group type: COMPARATOR
Intervention: Control group (smokers)
Number of subjects: 360
Study 17592075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol stent implantation (Bard Luminexx 3 stent)
Number of subjects: 244
Study 17592075 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 244
Study 16244488 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of 3 million IU of recombinant interleukin‐2 (rIL‐2) left intracyst after transvaginal ultrasound-guided drainage
Number of subjects: 24
Study 16244488 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 3 million IU of recombinant interleukin‐2 (rIL‐2) left intracyst after transvaginal ultrasound-guided drainage
Number of subjects: 24
Study 11862375 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 92
Study 11862375 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 92
Study 10211174 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release at 100, 150, or 300 mg/day for six weeks after target quit date (TQD)
Number of subjects: 615
Study 10211174 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release
Number of subjects: 615
Study 10211174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 8570432 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU with leucovorin (LV)
Number of subjects: 210
Study 8570432 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 210
Study 8570432 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 210
Study 2239164 — intervention group
Group type: EXPERIMENTAL
Intervention: Rydell four-flanged nail
Number of subjects: 200
Study 2239164 — intervention group
Group type: COMPARATOR
Intervention: Gouffon pins
Number of subjects: 200
Study 176034 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II infusion
Number of subjects: 0
Study 176034 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone infusion
Number of subjects: 0
Study 176034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid administration
Number of subjects: 0
Study 176034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid administration with both renin and ACTH suppression
Number of subjects: 0
Study 28786908 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty group
Number of subjects: 26
Study 27428680 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology taping applied in the first and second weeks postsurgery, each application lasting 5 days.
Number of subjects: 60
Study 27428680 — intervention group
Group type: COMPARATOR
Intervention: Standardized postoperative physiotherapy (Control group).
Number of subjects: 60
Study 25887581 — intervention group
Group type: EXPERIMENTAL
Intervention: Roland Morris Disability Questionnaire (RMDQ)
Number of subjects: 35
Study 25887581 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition questions
Number of subjects: 35
Study 25887581 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews
Number of subjects: 35
Study 23714270 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic support (monthly voucher of ZAR120.00)
Number of subjects: 4091
Study 23714270 — intervention group
Group type: COMPARATOR
Intervention: Usual tuberculosis care
Number of subjects: 4091
Study 16782096 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive women
Number of subjects: 106
Study 15617929 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld keratometry in upright position
Number of subjects: 33
Study 15617929 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld keratometry with rotation (5, 10, 15 degrees anticlockwise and clockwise)
Number of subjects: 33
Study 15617929 — intervention group
Group type: COMPARATOR
Intervention: Topographic keratometry
Number of subjects: 33
Study 10859436 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-adrenergic receptor antagonists (alpha-blockers) including prazosin, alfuzosin, indoramin, terazosin, doxazosin, and tamsulosin.
Number of subjects: 0
Study 10859436 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride.
Number of subjects: 0
Study 10859436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (alpha(1a)-receptor-selective blocker).
Number of subjects: 0
Study 10859436 — intervention group
Group type: COMPARATOR
Intervention: Other less selective alpha-blockers.
Number of subjects: 0
Study 10859436 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride and tamsulosin.
Number of subjects: 0
Study 8834935 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 70
Study 8834935 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 15 mg
Number of subjects: 70
Study 8834935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 1557677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten weekly sessions of counselling for parents of patients
Number of subjects: 36
Study 1557677 — intervention group
Group type: COMPARATOR
Intervention: Standard after-care of medication and support
Number of subjects: 36
Study 3912040 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCL; Paspertin)
Number of subjects: 19
Study 3912040 — intervention group
Group type: COMPARATOR
Intervention: Alizapride (AZP; Vergentan)
Number of subjects: 19
Study 31229206 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-hospitalization
Number of subjects: 30
Study 31229206 — intervention group
Group type: COMPARATOR
Intervention: Standard ambulatory hospital care
Number of subjects: 30
Study 28540870 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg OD
Number of subjects: 28
Study 28540870 — intervention group
Group type: COMPARATOR
Intervention: Placebo OD
Number of subjects: 28
Study 26189154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention strategy (CIS) including point‐of‐care CD4 testing, accelerated ART initiation, mobile phone appointment reminders, care and prevention packages, non‐cash financial incentives for linkage and retention.
Number of subjects: 2200
Study 26189154 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2200
Study 26189154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention strategy (CIS)
Number of subjects: 2200
Study 23321216 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered OGTT at home (unaided)
Number of subjects: 30
Study 23321216 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered OGTT in clinic (unaided but observed)
Number of subjects: 30
Study 23321216 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered OGTT performed by a nurse with laboratory glucose assays
Number of subjects: 30
Study 23321216 — intervention group
Group type: EXPERIMENTAL
Intervention: Device glucose measurements
Number of subjects: 30
Study 23321216 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat testing across settings
Number of subjects: 30
Study 23321216 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall OGTTs performed
Number of subjects: 30
Study 22009649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (Group A)
Number of subjects: 87
Study 22009649 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (Group B)
Number of subjects: 87
Study 19401478 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 19401478 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 0
Study 17476008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (250 kU)
Number of subjects: 41
Study 17476008 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional therapy)
Number of subjects: 41
Study 15564354 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (PSI) involving up to 16 sessions conducted in the home by a mental health worker.
Number of subjects: 291
Study 15564354 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 291
Study 11480804 — intervention group
Group type: COMPARATOR
Intervention: Nonabused children
Number of subjects: 70
Study 11480804 — intervention group
Group type: COMPARATOR
Intervention: Younger boys (abused)
Number of subjects: 70
Study 11480804 — intervention group
Group type: EXPERIMENTAL
Intervention: Abused children (more severe sexual abuse)
Number of subjects: 70
Study 11480804 — intervention group
Group type: EXPERIMENTAL
Intervention: Abused and nonabused children
Number of subjects: 70
Study 9543129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etidronate 400 mg/day for 14 days, followed by 76 days of oral calcium carbonate (500 mg elemental calcium), cycled over 12 months.
Number of subjects: 117
Study 9543129 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days, followed by 76 days of oral calcium carbonate (500 mg elemental calcium), cycled over 12 months.
Number of subjects: 117
Study 9543129 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate group
Number of subjects: 117
Study 9543129 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 117
Study 9543129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 117
Study 10155484 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-Valve (BV)
Number of subjects: 39
Study 10155484 — intervention group
Group type: COMPARATOR
Intervention: Demand-Valve (DV)
Number of subjects: 39
Study 2724504 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine sulfate (6 mg)
Number of subjects: 24
Study 2724504 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 24
Study 31058640 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 160
Study 31058640 — intervention group
Group type: EXPERIMENTAL
Intervention: Black coffee
Number of subjects: 160
Study 31058640 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 160
Study 31058640 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water
Number of subjects: 160
Study 31058640 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resins
Number of subjects: 160
Study 31058640 — intervention group
Group type: EXPERIMENTAL
Intervention: Test solutions
Number of subjects: 160
Study 28582810 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus supplementation
Number of subjects: 50
Study 28582810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25111465 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Improvement System Classwide Intervention Program (SSIS-CIP)
Number of subjects: 432
Study 25111465 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 432
Study 24195206 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Wenxin granule (9 g, 3 times a day for 4 weeks)
Number of subjects: 60
Study 24195206 — intervention group
Group type: COMPARATOR
Intervention: Wenxin granule alone (9 g, 3 times a day for 4 weeks)
Number of subjects: 60
Study 22145388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingavirin (90 mg once a day)
Number of subjects: 194
Study 22145388 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir (150 mg twice a day)
Number of subjects: 194
Study 22145388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingavirin
Number of subjects: 194
Study 22145388 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 194
Study 22145388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingavirin and Oseltamivir
Number of subjects: 194
Study 19332186 — intervention group
Group type: EXPERIMENTAL
Intervention: Free generic samples of hydrochlorothiazide for hypertensive patients
Number of subjects: 660
Study 19332186 — intervention group
Group type: EXPERIMENTAL
Intervention: Free generic samples of simvastatin for patients with hyperlipidemia
Number of subjects: 660
Study 19332186 — intervention group
Group type: EXPERIMENTAL
Intervention: Free generic samples (combined intervention)
Number of subjects: 660
Study 19332186 — intervention group
Group type: COMPARATOR
Intervention: No samples (control group)
Number of subjects: 660
Study 16357613 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (5 mg/kg) alone
Number of subjects: 19
Study 16357613 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) with methotrexate (20 mg/week)
Number of subjects: 19
Study 15612659 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing Bifidobacterium, Lactobacillus acidophilus and Enterococcus for 14 days
Number of subjects: 50
Study 15612659 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing Bacillus subtilis and Enterococcus faecium for 14 days
Number of subjects: 50
Study 11096238 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy TUMT (Prostasoft 2.5)
Number of subjects: 147
Study 11096238 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 147
Study 9279061 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folate supplementation
Number of subjects: 0
Study 9279061 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8354721 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush (M)
Number of subjects: 20
Study 8354721 — intervention group
Group type: EXPERIMENTAL
Intervention: Blend-a-Dent electric toothbrush (BL)
Number of subjects: 20
Study 8354721 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Plak Control (BPC)
Number of subjects: 20
Study 8354721 — intervention group
Group type: EXPERIMENTAL
Intervention: Interplak (IP)
Number of subjects: 20
Study 3789471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (salbutamol)
Number of subjects: 41
Study 31172821 — intervention group
Group type: EXPERIMENTAL
Intervention: Human stem cell-conditioned media (HSCM) applied after fractional CO2 laser
Number of subjects: 15